ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RVPH Reviva Pharmaceuticals Holdings Inc

3.80
-0.10 (-2.56%)
Last Updated: 15:43:49
Delayed by 15 minutes

Period:

Draw Mode:

Volume 523,251
Bid Price 3.81
Ask Price 3.82
News -
Day High 3.92

Low
2.67

52 Week Range

High
9.2499

Day Low 3.4401
Company Name Stock Ticker Symbol Market Type
Reviva Pharmaceuticals Holdings Inc RVPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.10 -2.56% 3.80 15:43:49
Open Price Low Price High Price Close Price Prev Close
3.78 3.4401 3.92 3.90
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,547 523,251 $ 3.73 $ 1,951,823 - 2.67 - 9.2499
Last Trade Time Type Quantity Stock Price Currency
15:43:49 21 $ 3.81 USD

Reviva Pharmaceuticals Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
198.19M 22.65M - 0 -24.34M -1.07 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Reviva Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RVPH Message Board. Create One! See More Posts on RVPH Message Board See More Message Board Posts

Historical RVPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.904.072.673.59602,4800.9031.03%
1 Month3.874.072.673.39337,362-0.07-1.81%
3 Months5.225.672.673.94342,768-1.42-27.20%
6 Months4.896.802.674.84824,236-1.09-22.29%
1 Year4.099.24992.675.00503,057-0.29-7.09%
3 Years5.999.500.534.69546,943-2.19-36.56%
5 Years9.469.610.534.71502,856-5.66-59.83%

Reviva Pharmaceuticals Description

Reviva Pharmaceuticals Holdings Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, respiratory, and metabolic diseases. The company is currently focused on the development of its lead product candidate, RP5063, which targets schizophrenia, bipolar disorder, major depressive disorder, behavioral & psychotic symptoms, dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, and also respiratory indications such as pulmonary arterial hypertension & idiopathic pulmonary fibrosis.

Your Recent History

Delayed Upgrade Clock